You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)旗下心血管複方新產品"氨氯地平阿託伐他汀鈣片"獲批
格隆匯 08-02 17:26

格隆匯8月2日丨中國生物製藥(01177.HK)宣佈,集團開發的心血管複方新產品"氨氯地平阿託伐他汀鈣片"(商品名:天依寧)已獲中國國家藥品監督管理局頒發藥品註冊證書。該產品按化學藥品4類申報,視同通過仿製藥質量和療效一致性評價,同品種國內仿製藥第二家獲批及第二家通過一致性評價。

高血壓與動脈粥樣硬化均可造成血管損傷,二者互為因果,互相促進,最終導致動脈粥樣硬化性心血管病,高血壓合併動脈粥樣硬化是發生心腦血管事件的極高危因素。氨氯地平阿託伐他汀鈣片可同時降低血壓和低密度脂蛋白膽固醇兩大致病因素,具有多重心血管保護效果,有利於最大程度降低心血管事件和死亡風險。

綜合管理是心血管疾病防治的發展趨勢。天依寧獲批上市,可為國內高血壓伴動脈粥樣硬化患者帶來更多用藥選擇,並有助於提升患者的疾病控制達成率。該產品將成為集團心血管產品線的重要一員。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account